Viatris Inc. (VTRS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Canonsburg, PA, United States. Der aktuelle CEO ist Scott Andrew Smith.
VTRS hat IPO-Datum 1980-03-17, 32,000 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $16.02B.
Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania, that develops and distributes a diverse portfolio of prescription brand drugs, generic medications, complex generics, biosimilars, and active pharmaceutical ingredients across four geographic segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company operates across multiple therapeutic areas including noncommunicable and infectious diseases, oncology, immunology, endocrinology, and ophthalmology, offering medicines in various formats such as oral solids, injectables, and complex dosage forms. Viatris markets well-known pharmaceutical brands including Lyrica, Lipitor, EpiPen, Viagra, and Celebrex, along with biosimilar franchises such as Fulphila and SEMGLEE, distributing its products through a broad network of pharmaceutical wholesalers, retailers, specialty pharmacies, and e-commerce channels. Beyond medications, the company provides patient support services including diagnostic clinics, educational seminars, and digital health tools. The company maintains strategic partnerships with leading biotechnology firms to expand its innovative pipeline and global reach.
